Overview

Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma

Status:
Recruiting

Trial end date:
2023-01-01

Target enrollment:

Participant gender:

Summary

A Phase II, multi-center, single-arm, non-blinded study combining androgen deprivation therapy (ADT) and pembrolizumab for patients with metastatic or locally recurrent androgen receptor-positive salivary gland carcinoma, not amenable to surgery or radiation.

Phase:

Phase 2

Details

Lead Sponsor:

Big Ten Cancer Research Consortium
Manish Patel

Collaborators:

Merck Sharp & Dohme Corp.
TerSera Therapeutics
TerSera Therapeutics LLC

Treatments:

Androgens
Goserelin
Pembrolizumab